Regulatory standard
Beyond-Use Dates for Compounded Drugs
BUD versus expiration; formulation; sterility; storage; testing; label instructions.
A beyond-use date is assigned by the compounding pharmacy. It is not a manufacturer expiry date and is derived differently. A manufacturer expiry date comes from formal stability testing across the product's shelf life under defined conditions. A beyond-use date comes from USP category rules and the pharmacy's own conditions.
Key findings
- A manufacturer expiry date comes from formal stability testing across the product's shelf life under defined conditions. A beyond-use date comes from USP category rules and the pharmacy
- Under Chapter 797, beyond-use dates for sterile preparations are short — commonly measured in days at room temperature — unless sterility testing extends them.
- A compounded preparation carrying an unusually long date warrants a direct question about the basis for it.
- A pharmacy that cannot state its beyond-use dating policy has not answered a basic quality question.
- Entity-specific compliance with this standard is not asserted on this page.
| Bud versus expiration | Verification Pending |
|---|---|
| Formulation | Verification Pending |
| Sterility | Verification Pending |
| Storage | Verification Pending |
| Testing | Verification Pending |
| Label instructions. | Verification Pending |
| Federal framework | License Verified FDA sources verified 2026-07-23 |
| Entity-specific data | Verification Pending |
What this standard actually requires
A beyond-use date is assigned by the compounding pharmacy. It is not a manufacturer expiry date and is derived differently.
A manufacturer expiry date comes from formal stability testing across the product's shelf life under defined conditions. A beyond-use date comes from USP category rules and the pharmacy's own conditions.
Under Chapter 797, beyond-use dates for sterile preparations are short — commonly measured in days at room temperature — unless sterility testing extends them.
A compounded preparation carrying an unusually long date warrants a direct question about the basis for it.
A pharmacy that cannot state its beyond-use dating policy has not answered a basic quality question.
What is established about bud versus expiration?
For compounded medication beyond use date, bud versus expiration is one of the elements this monitor tracks. The record that holds it is named in the source map below, and the verification state is shown in the snapshot above rather than asserted in prose.
Where bud versus expiration has not been checked against that source at this snapshot, the field renders Verification Pending. That is a statement about this platform's verification state and carries no implication about any entity.
What is established about formulation?
For compounded medication beyond use date, formulation is one of the elements this monitor tracks. The record that holds it is named in the source map below, and the verification state is shown in the snapshot above rather than asserted in prose.
Where formulation has not been checked against that source at this snapshot, the field renders Verification Pending. That is a statement about this platform's verification state and carries no implication about any entity.
What is established about sterility?
For compounded medication beyond use date, sterility is one of the elements this monitor tracks. The record that holds it is named in the source map below, and the verification state is shown in the snapshot above rather than asserted in prose.
Where sterility has not been checked against that source at this snapshot, the field renders Verification Pending. That is a statement about this platform's verification state and carries no implication about any entity.
What is established about storage?
For compounded medication beyond use date, storage is one of the elements this monitor tracks. The record that holds it is named in the source map below, and the verification state is shown in the snapshot above rather than asserted in prose.
Where storage has not been checked against that source at this snapshot, the field renders Verification Pending. That is a statement about this platform's verification state and carries no implication about any entity.
What is established about testing?
For compounded medication beyond use date, testing is one of the elements this monitor tracks. The record that holds it is named in the source map below, and the verification state is shown in the snapshot above rather than asserted in prose.
Where testing has not been checked against that source at this snapshot, the field renders Verification Pending. That is a statement about this platform's verification state and carries no implication about any entity.
What does this page establish?
It establishes the framework and the source map for compounded medication beyond use date, drawn from FDA primary sources verified on 2026-07-23. Framework facts — what the statute says, what registration means, which agency holds which record — are stable and checkable, and they are cited inline.
What it does not establish is any entity-specific fact. This platform separates those two categories deliberately, because they carry different verification burdens. A statutory definition can be cited once and relied on; a pharmacy's licence status changes continuously and must be checked at the moment of use.
What this means
- The framework governing compounded medication beyond use date is cited to FDA primary sources.
- The record holding each element of bud versus expiration is named.
- Verification dates are published on every field so staleness is visible.
What this does not mean
- That any entity connected with compounded medication beyond use date is compliant or non-compliant.
- That the absence of a record indicates the absence of an issue.
- That this platform certifies or endorses any facility or preparation.
Status terms on this page follow the platform's published status vocabulary.
- No entity-specific record relating to compounded medication beyond use date has been verified at this snapshot.
- BUD versus expiration may change without notice to this platform.
- Regulatory positions change through rulemaking, guidance, and enforcement action.
- Records held by different agencies may disagree; conflicts are published as conflicts.
Sources verified for this page — 10 sources
- FDA — Information for Outsourcing Facilitieschecked 2026-07-23
- FDA — Q&A: Outsourcing Facility Registrationchecked 2026-07-23
- FDA — Registered Outsourcing Facilitieschecked 2026-07-23
- FDA — Aligning Federal and State Regulation of Compounderschecked 2026-07-23
- FDA — Outsourcing Facility Feeschecked 2026-07-23
- FDA — Compounded Drug Products That Are Essentially Copieschecked 2026-07-23
- FDA — Proposes to Exclude Semaglutide, Tirzepatide and Liraglutide from 503B Bulks List (30 Apr 2026)checked 2026-07-23
- FDA — Registration of Human Drug Compounding Outsourcing Facilities (guidance)checked 2026-07-23
- Nevada Board of Pharmacy — Notice of FDA Declaratory Orders (tirzepatide, semaglutide)checked 2026-07-23
- FDA — Outsourcing Facility Fees guidancechecked 2026-07-23
Why compounded medication beyond use date is hard to verify
Three structural features of compounding oversight make verification harder than it looks, and they apply to this topic as much as any other.
First, authority is split. Federal and state regulators hold different records about the same entity, and neither register is complete on its own. Second, registration and inspection are separate events — a facility can be registered for years without an inspection, so a registration date tells you nothing about oversight intensity. Third, a record's currency is invisible without its date: a licence verified last year and a licence verified today look identical in a citation.
That is why every field on this platform carries a check date, and why a field without one renders as pending rather than as a fact.
| Structural feature | Consequence for verification | How this platform handles it |
|---|---|---|
| Split federal and state authority | No single register is complete for any entity | Both systems are named per field, and neither is presented as sufficient |
| Registration precedes inspection | A registration is not evidence of oversight | Registration and inspection are reported as separate facts |
| Records go stale silently | A citation without a date implies currency it may not have | Every field carries its own verification date |
| Observations are not findings | A Form 483 is frequently reported as a violation | Observations and final actions are stored and displayed separately |
| Resolved actions persist online | Closed matters get reported as current | Current and historical status are distinct states, never merged |
Related records in this section
Section hub: Regulatory standards · Methodology · Status definitions · Right to respond
Frequently asked questions
What does this page cover on compounded medication beyond use date?
BUD versus expiration; formulation; sterility; storage; testing; label instructions.
What is established about bud versus expiration?
BUD versus expiration is tracked as part of compounded medication beyond use date. The record holding it is named in the source map on this page, and its verification state is shown in the status snapshot rather than asserted in prose.
What is established about formulation?
formulation is tracked as part of compounded medication beyond use date. The record holding it is named in the source map on this page, and its verification state is shown in the status snapshot rather than asserted in prose.
What is established about sterility?
sterility is tracked as part of compounded medication beyond use date. The record holding it is named in the source map on this page, and its verification state is shown in the status snapshot rather than asserted in prose.
Which agency holds the record behind compounded medication beyond use date?
Federal registration and inspection records sit with FDA; licensure and discipline sit with the relevant state board of pharmacy. The two systems are separate and must both be checked.
Sources
- FDA — Information for Outsourcing Facilities
- FDA — Q&A: Outsourcing Facility Registration
- FDA — Registered Outsourcing Facilities
- FDA — Aligning Federal and State Regulation of Compounders
- FDA — Outsourcing Facility Fees
- FDA — Compounded Drug Products That Are Essentially Copies
- FDA — Proposes to Exclude Semaglutide, Tirzepatide and Liraglutide from 503B Bulks List (30 Apr 2026)
- FDA — Registration of Human Drug Compounding Outsourcing Facilities (guidance)
- Nevada Board of Pharmacy — Notice of FDA Declaratory Orders (tirzepatide, semaglutide)
- FDA — Outsourcing Facility Fees guidance
Update history
| Date | Change |
|---|---|
| 2026-07-23 | Record published at current snapshot. |
Dates change only for substantive updates. Entities may submit a correction or response through the right-to-respond process.